Skip to main navigation Skip to search Skip to main content

Identification of a novel TGFB1 variant in a patient with Camurati-Engelmann disease responsive to alendronate

Research output: Contribution to journalLetter (Academic Journal)peer-review

Abstract

Whole genome sequencing and alendronate may be of value in diagnosing and managing CED, respectively.
Original languageEnglish
Pages (from-to)6427-6429
Number of pages3
JournalRheumatology
Volume64
Issue number12
Early online date14 Aug 2025
DOIs
Publication statusPublished - 1 Dec 2025

Bibliographical note

Copyright © 2025, © The Author(s) 2025. Published by Oxford University Press on behalf of the British Society for Rheumatology.

Fingerprint

Dive into the research topics of 'Identification of a novel TGFB1 variant in a patient with Camurati-Engelmann disease responsive to alendronate'. Together they form a unique fingerprint.

Cite this